GenMark Diagnostics Inc. (NASDAQ:GNMK) rose 3.8% during mid-day trading on Wednesday . The company traded as high as $9.30 and last traded at $9.26, with a volume of 136,097 shares traded. The stock had previously closed at $8.92.

GNMK has been the topic of a number of recent analyst reports. Needham & Company LLC initiated coverage on GenMark Diagnostics in a research report on Friday, June 17th. They set a “buy” rating and a $13.00 target price on the stock. JPMorgan Chase & Co. upped their price target on GenMark Diagnostics from $10.00 to $13.00 and gave the company an “overweight” rating in a research report on Friday, July 29th. Canaccord Genuity reissued a “buy” rating and set a $8.00 price target on shares of GenMark Diagnostics in a research report on Wednesday, May 4th. Finally, Zacks Investment Research raised GenMark Diagnostics from a “hold” rating to a “buy” rating and set a $11.00 price target on the stock in a research report on Tuesday, August 2nd. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $10.39.

The stock’s market cap is $387.80 million. The company’s 50-day moving average price is $9.63 and its 200 day moving average price is $7.01.

GenMark Diagnostics (NASDAQ:GNMK) last announced its quarterly earnings data on Thursday, July 28th. The company reported ($0.30) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.33) by $0.03. During the same quarter in the previous year, the business posted ($0.29) earnings per share. The firm earned $12.50 million during the quarter, compared to the consensus estimate of $9.62 million. The firm’s quarterly revenue was up 63.6% on a year-over-year basis. Analysts forecast that GenMark Diagnostics Inc. will post ($1.17) EPS for the current fiscal year.

A hedge fund recently raised its stake in GenMark Diagnostics stock. I.G. Investment Management LTD. boosted its position in shares of GenMark Diagnostics Inc. (NASDAQ:GNMK) by 0.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 134,589 shares of the company’s stock after buying an additional 978 shares during the period. I.G. Investment Management LTD. owned 0.32% of GenMark Diagnostics worth $1,044,000 as of its most recent filing with the SEC.

GenMark Diagnostics, Inc (GenMark) is a molecular diagnostics company. The Company focuses on developing and commercializing its eSensor detection technology. Its eSensor electrochemical technology detects multiple distinct biomarkers in a single sample. It sells its XT-8 instrument and related diagnostic and research tests (XT-8 system) in the United States.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.